A citation-based method for searching scientific literature


List of co-cited articles
36 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Racial differences in the use of BRCA1/2 testing among women with a family history of breast or ovarian cancer.
Katrina Armstrong, Ellyn Micco, Amy Carney, Jill Stopfer, Mary Putt. JAMA 2005
281
26

Randomized noninferiority trial of telephone versus in-person genetic counseling for hereditary breast and ovarian cancer.
Marc D Schwartz, Heiddis B Valdimarsdottir, Beth N Peshkin, Jeanne Mandelblatt, Rachel Nusbaum, An-Tsun Huang, Yaojen Chang, Kristi Graves, Claudine Isaacs, Marie Wood,[...]. J Clin Oncol 2014
148
26

A brief assessment of concerns associated with genetic testing for cancer: the Multidimensional Impact of Cancer Risk Assessment (MICRA) questionnaire.
David Cella, Chanita Hughes, Amy Peterman, Chih-Hung Chang, Beth N Peshkin, Marc D Schwartz, Lari Wenzel, Amy Lemke, Alfred C Marcus, Caryn Lerman. Health Psychol 2002
166
20

Essential elements of genetic cancer risk assessment, counseling, and testing: updated recommendations of the National Society of Genetic Counselors.
Bronson D Riley, Julie O Culver, Cécile Skrzynia, Leigha A Senter, June A Peters, Josephine W Costalas, Faith Callif-Daley, Sherry C Grumet, Katherine S Hunt, Rebecca S Nagy,[...]. J Genet Couns 2012
185
20

Telephoned BRCA1/2 genetic test results: prevalence, practice, and patient satisfaction.
L Baumanis, J P Evans, N Callanan, L R Susswein. J Genet Couns 2009
53
20

Models of service delivery for cancer genetic risk assessment and counseling.
Angela M Trepanier, Dawn C Allain. J Genet Couns 2014
48
20

Assessment of clinical practices among cancer genetic counselors.
Deborah Wham, Thuy Vu, Gayun Chan-Smutko, Christine Kobelka, Diana Urbauer, Brandie Heald. Fam Cancer 2010
41
13



Knowledge, attitudes and beliefs of Arabic-Australians concerning cancer.
Mona Saleh, Kristine Barlow-Stewart, Bettina Meiser, Kathy Tucker, Maurice Eisenbruch, Judy Kirk. Psychooncology 2012
15
13

Catalysts to withdrawal from familial ovarian cancer screening for surgery and reactions to discontinued screening: a qualitative study.
Kate J Lifford, Alison Clements, Lindsay Fraser, Deborah Lancastle, Kate Brain. Fam Cancer 2013
5
40

Telephone genetic counseling for high-risk women undergoing BRCA1 and BRCA2 testing: rationale and development of a randomized controlled trial.
Beth N Peshkin, Tiffani A Demarco, Kristi D Graves, Karen Brown, Rachel H Nusbaum, Diana Moglia, Andrea Forman, Heiddis Valdimarsdottir, Marc D Schwartz. Genet Test 2008
42
13

Underutilization of BRCA1/2 testing to guide breast cancer treatment: black and Hispanic women particularly at risk.
Douglas E Levy, Stacey D Byfield, Catherine B Comstock, Judy E Garber, Sapna Syngal, William H Crown, Alexandra E Shields. Genet Med 2011
152
13

Impact of Event Scale: a measure of subjective stress.
M Horowitz, N Wilner, W Alvarez. Psychosom Med 1979
13

Identification of genetic counseling service delivery models in practice: a report from the NSGC Service Delivery Model Task Force.
Stephanie A Cohen, Monica L Marvin, Bronson D Riley, Hetal S Vig, Julie A Rousseau, Shanna L Gustafson. J Genet Couns 2013
74
13

Report from the National Society of Genetic Counselors service delivery model task force: a proposal to define models, components, and modes of referral.
Stephanie A Cohen, Shanna L Gustafson, Monica L Marvin, Bronson D Riley, Wendy R Uhlmann, S Bonnie Liebers, Julie A Rousseau. J Genet Couns 2012
45
13


Delivery of Internet-based cancer genetic counselling services to patients' homes: a feasibility study.
Neal J Meropol, Mary B Daly, Hetal S Vig, Frank J Manion, Sharon L Manne, Carla Mazar, Camara Murphy, Nicholas Solarino, Vadim Zubarev. J Telemed Telecare 2011
34
13

Retrospective comparison of patient outcomes after in-person and telephone results disclosure counseling for BRCA1/2 genetic testing.
Courtney Doughty Rice, Jennifer Gamm Ruschman, Lisa J Martin, Jennifer B Manders, Erin Miller. Fam Cancer 2010
18
13



More breast cancer patients prefer BRCA-mutation testing without prior face-to-face genetic counseling.
Aisha S Sie, Wendy A G van Zelst-Stams, Liesbeth Spruijt, Arjen R Mensenkamp, Marjolijn J L Ligtenberg, Han G Brunner, Judith B Prins, Nicoline Hoogerbrugge. Fam Cancer 2014
30
13

Genetic testing for familial/hereditary breast cancer-comparison of guidelines and recommendations from the UK, France, the Netherlands and Germany.
Dorothea Gadzicki, D Gareth Evans, Hilary Harris, Claire Julian-Reynier, Irmgard Nippert, Jörg Schmidtke, Aad Tibben, Christi J van Asperen, Brigitte Schlegelberger. J Community Genet 2011
52
13

Development of cancer genetic services in the UK: A national consultation.
Ingrid Slade, Daniel Riddell, Clare Turnbull, Helen Hanson, Nazneen Rahman. Genome Med 2015
25
13

Are videoconferenced consultations as effective as face-to-face consultations for hereditary breast and ovarian cancer genetic counseling?
Elvira M Zilliacus, Bettina Meiser, Elizabeth A Lobb, Patrick J Kelly, Kristine Barlow-Stewart, Judy A Kirk, Alan D Spigelman, Linda J Warwick, Katherine M Tucker. Genet Med 2011
42
13

Incidence and predictors of positive and negative effects of BRCA1/2 genetic testing on familial relationships: a 3-year follow-up study.
Julie Lapointe, Karine Bouchard, Andrea Farkas Patenaude, Elizabeth Maunsell, Jacques Simard, Michel Dorval. Genet Med 2012
6
33

Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance.
Marc D Schwartz, Claudine Isaacs, Kristi D Graves, Elizabeth Poggi, Beth N Peshkin, Christy Gell, Clinton Finch, Scott Kelly, Kathryn L Taylor, Lauren Perley. Cancer 2012
90
13

Health Care Segregation, Physician Recommendation, and Racial Disparities in BRCA1/2 Testing Among Women With Breast Cancer.
Anne Marie McCarthy, Mirar Bristol, Susan M Domchek, Peter W Groeneveld, Younji Kim, U Nkiru Motanya, Judy A Shea, Katrina Armstrong. J Clin Oncol 2016
73
13

Interventions to improve patient education regarding multifactorial genetic conditions: a systematic review.
Katherine G Meilleur, Marguerite T Littleton-Kearney. Am J Med Genet A 2009
27
13


A high frequency of BRCA mutations in young black women with breast cancer residing in Florida.
Tuya Pal, Devon Bonner, Deborah Cragun, Alvaro N A Monteiro, Catherine Phelan, Lily Servais, Jongphil Kim, Steven A Narod, Mohammad R Akbari, Susan T Vadaparampil. Cancer 2015
50
13

African American women's limited knowledge and experiences with genetic counseling for hereditary breast cancer.
Vanessa B Sheppard, Kristi D Graves, Juleen Christopher, Alejandra Hurtado-de-Mendoza, Costellia Talley, Karen Patricia Williams. J Genet Couns 2014
31
13

Racial disparities in BRCA testing and cancer risk management across a population-based sample of young breast cancer survivors.
Deborah Cragun, Anne Weidner, Courtney Lewis, Devon Bonner, Jongphil Kim, Susan T Vadaparampil, Tuya Pal. Cancer 2017
82
13

American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility.
Mark E Robson, Angela R Bradbury, Banu Arun, Susan M Domchek, James M Ford, Heather L Hampel, Stephen M Lipkin, Sapna Syngal, Dana S Wollins, Noralane M Lindor. J Clin Oncol 2015
296
13

The Global State of the Genetic Counseling Profession.
MaryAnn Abacan, Lamia Alsubaie, Kristine Barlow-Stewart, Beppy Caanen, Christophe Cordier, Eliza Courtney, Emeline Davoine, Janice Edwards, Niby J Elackatt, Kate Gardiner,[...]. Eur J Hum Genet 2019
66
13


Variation of O(6)-methylguanine-DNA methyltransferase (MGMT) promoter methylation in serial samples in glioblastoma.
Jonathon F Parkinson, Helen R Wheeler, Adele Clarkson, Catriona A McKenzie, Michael T Biggs, Nicholas S Little, Raymond J Cook, Marinella Messina, Bruce G Robinson, Kerrie L McDonald. J Neurooncol 2008
75
6

Phase I/IIa study of cilengitide and temozolomide with concomitant radiotherapy followed by cilengitide and temozolomide maintenance therapy in patients with newly diagnosed glioblastoma.
Roger Stupp, Monika E Hegi, Bart Neyns, Roland Goldbrunner, Uwe Schlegel, Paul M J Clement, Gerhard G Grabenbauer, Adrian F Ochsenbein, Matthias Simon, Pierre-Yves Dietrich,[...]. J Clin Oncol 2010
311
6

Low-dose fotemustine for recurrent malignant glioma: a multicenter phase II study.
Alessandra Fabi, Giulio Metro, Antonello Vidiri, Gaetano Lanzetta, Mariantonia Carosi, Stefano Telera, Marta Maschio, Michelangelo Russillo, Isabella Sperduti, Carmine M Carapella,[...]. J Neurooncol 2010
10
10

Frequent promoter hypermethylation and low expression of the MGMT gene in oligodendroglial tumors.
Maria Möllemann, Marietta Wolter, Jörg Felsberg, V Peter Collins, Guido Reifenberger. Int J Cancer 2005
217
6


Extent and patterns of MGMT promoter methylation in glioblastoma- and respective glioblastoma-derived spheres.
Davide Sciuscio, Annie-Claire Diserens, Kristof van Dommelen, Danielle Martinet, Greg Jones, Robert-Charles Janzer, Claudio Pollo, Marie-France Hamou, Bernd Kaina, Roger Stupp,[...]. Clin Cancer Res 2011
58
6

Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort.
Philippe Metellus, Bema Coulibaly, Isabelle Nanni, Frederic Fina, Nathalie Eudes, Roch Giorgi, Marylin Barrie, Olivier Chinot, Stephane Fuentes, Henry Dufour,[...]. Cancer 2009
60
6

Optimal role of temozolomide in the treatment of malignant gliomas.
Roger Stupp, Martin J van den Bent, Monika E Hegi. Curr Neurol Neurosci Rep 2005
118
6

Prognostic significance of the immunohistochemical expression of O6-methylguanine-DNA methyltransferase, P-glycoprotein, and multidrug resistance protein-1 in glioblastomas.
Takao Nakagawa, Kazunori Ido, Takahiro Sakuma, Hiroaki Takeuchi, Kazufumi Sato, Toshihiko Kubota. Neuropathology 2009
28
6

Relationship between expression of O6-methylguanine-DNA methyltransferase, glutathione-S-transferase pi in glioblastoma and the survival of the patients treated with nimustine hydrochloride: an immunohistochemical analysis.
Takeo Anda, Hamisi Kimaro Shabani, Keishi Tsunoda, Yoshiharu Tokunaga, Makio Kaminogo, Shobu Shibata, Tomayoshi Hayashi, Masachika Iseki. Neurol Res 2003
46
6

MGMT immunohistochemical expression and promoter methylation in human glioblastoma.
Fausto J Rodriguez, Stephen N Thibodeau, Robert B Jenkins, Karen V Schowalter, Bolette L Caron, Brian P O'neill, Charles David James, Sandra Passe, Jeff Slezak, Caterina Giannini. Appl Immunohistochem Mol Morphol 2008
89
6


MGMT promoter methylation in malignant gliomas: ready for personalized medicine?
Michael Weller, Roger Stupp, Guido Reifenberger, Alba A Brandes, Martin J van den Bent, Wolfgang Wick, Monika E Hegi. Nat Rev Neurol 2010
456
6

Careful exclusion of non-neoplastic brain components is required for an appropriate evaluation of O6-methylguanine-DNA methyltransferase status in glioma: relationship between immunohistochemistry and methylation analysis.
Ken Sasai, Miho Nodagashira, Hiroshi Nishihara, Eiko Aoyanagi, Lei Wang, Masahito Katoh, Junichi Murata, Yoshimaru Ozaki, Tamio Ito, Shin Fujimoto,[...]. Am J Surg Pathol 2008
54
6


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.